Quality of life improves significantly following real-world oral immunotherapy for peanut- allergic children.

Peanut Oral Immunotherapy (POIT) is a novel and active form of treatment with multiple research studies supporting its efficacy and safety, but there are limited data available on patients ’ quality of life changes following successful desensitization. FDA recently approved the first drug for POIT commercial use.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research